CAPTRUST Financial Advisors
KZIA

CAPTRUST Financial Advisors’s Kazia Therapeutics KZIA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-305
Closed -$6.56K – 2350
2024
Q3 		$6.56K Buy
+305
New +$6.09K ﹤0.01% 2281

Other funds holding KZIA

MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

CAPTRUST Financial Advisors's KZIA Position: Q4 2024 in Review

CAPTRUST Financial Advisors sold out of Kazia Therapeutics (KZIA) in Q4 2024, closing a stake of 305 shares — an estimated $6.56K sold.

CAPTRUST Financial Advisors first reported a position in KZIA in Q3 2024 and held it in 1 quarter. The position peaked at $6.56K in Q3 2024. 10 funds tracked by Wall St. Rank hold KZIA as of Q4 2024.

  • CAPTRUST Financial Advisors reported no remaining Kazia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 305 Kazia Therapeutics shares in Q4 2024, an estimated $6.56K.
  • CAPTRUST Financial Advisors first reported a position in Kazia Therapeutics in Q3 2024 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Kazia Therapeutics position peaked at $6.56K in Q3 2024.
  • 10 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q4 2024.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.